Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Overview

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Companies Involved in Therapeutics Development

Jyant Technologies Inc

Neurotez Inc

Regeneron Pharmaceuticals Inc

XL-protein GmbH

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Drug Profiles

Allo-Aca - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CV-08 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

memtin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

metreleptin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptide to Antagonize Leptin Receptor II for Triple Negative Breast Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Agonize Leptin Receptor for Obesity - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REGN-4461 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XL-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Dormant Products

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Discontinued Products

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Product Development Milestones

Featured News & Press Releases

Aug 23, 2018: Novelion Therapeutics announces next phase of operational improvements

Jul 31, 2018: Novelion Therapeutics Announces Marketing Authorization for MYALEPTA (metreleptin) in the European Union to Treat Generalized and Partial Lipodystrophy

Jun 25, 2018: Novelion Therapeutics Announces Presentation of Positive Metreleptin Data at American Diabetes Association Scientific Sessions

Jun 01, 2018: MYALEPTA (metreleptin) Receives Positive CHMP Opinion in Patients with Generalized and Partial Lipodystrophy

Sep 15, 2017: Metreleptin and Lipodystrophy Data Presented at the International Meeting of Pediatric Endocrinology

Jun 12, 2017: Novelion Therapeutics Announces Presentation of Metreleptin Data at American Diabetes Association

May 05, 2017: Novelion Therapeutics Announces Presentation of Metreleptin Data at American Association of Clinical Endocrinology

Apr 04, 2017: Metreleptin and Lipodystrophy Data Presented at the Annual Meeting of the Endocrine Society

Mar 30, 2017: Novelion Therapeutics Subsidiary Announces New Data to be Presented at the Annual Meeting of the Endocrine Society

Jan 23, 2017: Novelion Therapeutics Announces Acceptance of Marketing Authorization Application for Metreleptin by European Medicines Agency

Dec 22, 2016: Novelion Therapeutics Subsidiary Files for European Approval for Metreleptin as a treatment for Generalized Lipodystrophy and a Subset of Patients with Partial Lipodystrophy

Nov 03, 2016: Aegerion Pharmaceuticals appoints John Orloff as Executive Vice President Head of R&D

Nov 03, 2016: Aegerion Pharmaceuticals appoints John Orloff as Executive Vice President, Head of R&D

Nov 03, 2016: Aegerion Pharmaceuticals appoints John Orloff, M.D., as Executive Vice President, Head of R&D

Feb 25, 2014: FDA approves Myalept to treat rare metabolic disease

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Pipeline Review, H1 2019

Summary

According to the recently published report 'Leptin Receptor - Pipeline Review, H1 2019'; Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) pipeline Target constitutes close to 7 molecules.

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Leptin receptor or LEP-R is a protein encoded by the LEPR gene. It acts as a receptor for hormone LEP/leptin. Upon binding it mediates LEP central and peripheral effects through the activation of different signaling pathways such as JAK2/STAT3 and MAPK cascade. LEP acts as an appetite-regulating factor that induces a decrease in food intake and an increase in energy consumption by inducing anorexinogenic factors and suppressing orexigenic neuropeptides also regulates bone mass and secretion of hypothalamo-pituitary-adrenal hormones. In the periphery increases basal metabolism, influences reproductive function, regulates pancreatic beta-cell function and insulin secretion, is pro-angiogenic and affects innate and adaptive immunity.

The report 'Leptin Receptor - Pipeline Review, H1 2019' outlays comprehensive information on the Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase I and Preclinical stages are 1 and 6 respectively. Report covers products from therapy areas Metabolic Disorders, Central Nervous System, Oncology and Ophthalmology which include indications Obesity, Lipodystrophy (Lipoatrophy), Alzheimer's Disease, Breast Cancer, Choroidal Neovascularization, Type 1 Diabetes (Juvenile Diabetes) and Type 2 Diabetes.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR)
- The report reviews Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics and enlists all their major and minor projects
- The report assesses Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope